GlobeNewsWire
29 Sept 2026, 12:45 UTC · 1h ago
Verdict
Headline takes no side. We score MBRX +0.60 across four claims — strongly bullish.
+0.60strongly bullish
More positive than 77% of ticker scores this week
What the story claims
4 claims · scored −1 bearish … +1 bullish · 4 new · 0 priced in
Moleculin Biotech has completed enrollment for Part A of the Phase 2/3 MIRACLE trial with 89 subjects.
Newannounced today, Sept. 29, 2026
More positive than 79% of claims this week
The company is on track for a comprehensive Part A data readout in the first quarter of 2027.
New
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 2 movers · tap to explore
So whatThis establishes the primary catalyst horizon for MBRX stock over the next 4-6 months.
More positive than 66% of claims this week
The Part A subject composition shifted to an estimated 50/50 split between 'fit' and 'unfit' subjects, compared to 70/30 in the first 45 subjects.
Newannounced today, Sept. 29, 2026
So whatIncreasing the proportion of 'unfit' patients by 20% creates a more challenging environment for achieving the remission rates needed for success.
More negative than 68% of claims this week
Blinded data from the MIRACLE trial continues to show a lack of cardiotoxicity.
Newannounced today, Sept. 29, 2026
More positive than 54% of claims this week
Which stocks this story touches
More positive than 77% of ticker scores this week
The company successfully completed enrollment for a pivotal Phase 2/3 trial and remains on track for a Q1 2027 data readout.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Invezz
2h ago
—
MBRX hasn't traded since this ran. Last close $0.5690 (Sep 28); the reaction starts at the next open.
MBRX chart →
